IP Verse

Anti-Pd-1 Antibodies And Compositions - EP3368572

The patent EP3368572 was granted to LES Laboratoires Servier on Apr 26, 2023. The application was originally filed on Sep 30, 2016 under application number EP16774691A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3368572

LES LABORATOIRES SERVIER
Application Number
EP16774691A
Filing Date
Sep 30, 2016
Status
Granted And Under Opposition
Apr 22, 2022
Grant Date
Apr 26, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFIFeb 24, 2023ZWICKERWITHDRAWN

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP3026062
OPPOSITIONEP3081576
OPPOSITIONWO2014206107
OPPOSITIONWO2015085847
OPPOSITIONWO2015112800
OPPOSITIONWO2016106159

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Camrelizumab", WHO Drug Information. International Nonproprietary Names for Pharmaceutical Substances (INN), (20170101), vol. 31, no. 1, pages 74 - 75, XP093030420-
OPPOSITION- Anonymous, "Recommended INN: List 81; cemiplimab", WHO Drug Information, (20190101), vol. 33, no. 1, pages 57 - 58, XP093030418-
OPPOSITION- Anonymous, "Toripalimab", WHO Drug Information. International Nonproprietary Names for Pharmaceutical Substances (INN), (20190101), vol. 33, no. 1, pages 124 - 125, XP093030423-
OPPOSITION- Liu Hongchuan, Et Al, "Glycosylation-independent binding of monoclonal antibody toripalimab to FG loopof PD-1 for tumor immune checkpoint therapy", MABS, (20190101), vol. 11, no. 4, pages 681 - 690, XP093030409-
OPPOSITION- Lu Dan, Et Al, "PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy", Frontiers in Immunology, (20220301), vol. 13, pages 1 - 11, XP093030411-
OPPOSITION- Canziani, G.A, Klakamp, S. , Myszka, D.G., "Kinetic screening of antibodies from crude hybridoma samples using Biacore", Analytical Biochemistry, Amsterdam, NL , (20040215), vol. 325, no. 2, doi:10.1016/j.ab.2003.11.004, ISSN 0003-2697, pages 301 - 307, XP004486087
OPPOSITION- Burova Elena, Hermann Aynur, Dai Jie, Ullman Erica, Halasz Gabor, Potocky Terra, Hong Seongwon, Liu Matt, Allbritton Omaira, Woodruff Amy, Pei Jerry, Rafique Ashique, Poueymirou William, Martin Joel, Macdonald Douglas, Olson William C., Murphy Andrew, Ioffe Ella, Thurston Gavin, Mohrs Markus, "Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 -Knockin Mice", Molecular Cancer Therapeutics, US , (20191101), vol. 18, no. 11, doi:10.1158/1535-7163.MCT-18-1376, ISSN 1535-7163, pages 2051 - 2062, XP093053770
OPPOSITION- Liu Kefang, Tan Shuguang, Jin Wanjun, Guan Jiawei, Wang Qingling, Sun Huan, Qi Jianxun, Yan Jinghua, Chai Yan, Wang Zhongfu, Deng Chuxia, Gao George F, "N-glycosylation of PD-1 promotes binding of camrelizumab", EMBO REPORTS, NATURE PUBLISHING GROUP, LONDON, GB, GB , (20201203), vol. 21, no. 12, doi:10.15252/embr.202051444, ISSN 1469-221X, XP055789000

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents